A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
Status:
Recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to
evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in
subjects with advanced solid tumors or lymphoma.